{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.1","value":"17.2"}]}],"title":"IL-6 level range"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.025","value":"0.039"}]}],"title":"MIP-1 level range"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.066","value":"0.084"}]}],"title":"VEGF level range"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.11","value":"0.12"}]}],"title":"VEGFR1 level range"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.08","value":"8.85"}]}],"title":"VEGFR2 level range"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"A Wilconxon signed-rank test conducted to determine if biomarker levels differed between baseline levels and those after three full cycles of treatment for all patients.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"OG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at Baseline","type":"SECONDARY","unitOfMeasure":"mg per liter"}